American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 418.e1-418.e7, April 2008

Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary

  • Elin Ødegaard, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
    • ,
  • Bente Vilming Elgaaen, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Magne K. Fagerhol, MD, PhD

      Affiliations

    • Department of Immunology and Transfusion Medicine, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.
    • ,
  • Vibeke Engh, MD

      Affiliations

    • Department of Pathology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Mathias Onsrud, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.
    • ,
  • Anne Cathrine Staff, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway.

Received 18 June 2007; received in revised form 3 October 2007; accepted 11 October 2007. published online 13 February 2008.

Objective

Recent studies indicate that circulating calprotectin may serve as a biomarker in some cancers. We investigated whether this is the case for ovarian neoplasms.

Study Design

Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71). Serum CA 125 was analyzed in the same study population.

Results

Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P< .001). A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma. Receiver operating characteristic curves demonstrated a larger area under the curve for CA 125 (0.85) as compared with calprotectin (0.70).

Conclusion

Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.

Key words: calprotectin, inflammation, ovarian cancer, ovarian neoplasm

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The work of E.Ø. is supported by research grants from Ulleval University Hospital (Vitenskapsradet Ulleval universitetssykehus) and the Eastern Norway Regional Health Authority.

 Reprints not available from the authors.

 Cite this article as: Ødegaard E, Davidson B, Elgaaen BV, et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 2008;198:418.e1-418.e7.

PII: S0002-9378(07)02014-5

doi:10.1016/j.ajog.2007.10.792

American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 418.e1-418.e7, April 2008

Article Tools

* Image Usage & Resolution